Treatment of discoid lupus erythematosus with crisaborole
Crisaborole, a topical phosphodiesterase-4 inhibitor approved for atopic dermatitis, may represent a well-tolerated nonsteroidal therapeutic option for facial DLE, particularly in patients who are unresponsive to or intolerant of conventional treatments. Further studies are needed to clarify its efficacy and long-term safety in DLE.
Authors
- Deyu Song (ORCID: https://orcid.org/0000-0001-9514-0740)
- Huan Liu (ORCID: https://orcid.org/0000-0003-4642-4485)
- Xiaoming Feng (ORCID: https://orcid.org/0000-0002-7743-0952)
- Yun Dai (ORCID: https://orcid.org/0009-0009-4285-8332)
- Xian Jiang
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1080/09546634.2026.2638633
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00